Carregant...
Mechanisms of K(v)2.1 channel inhibition by celecoxib – modification of gating and channel block
BACKGROUND AND PURPOSE: Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex) were developed as NSAIDs with reduced gastric side effects. Celecoxib has now been shown to affect cellular physiology via an unexpected, COX-independent, pathway – by inhibiting...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Publishing Ltd
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2825362/ https://ncbi.nlm.nih.gov/pubmed/20015088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2009.00539.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|